Borkow G - Search Results

1

Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone.

Borkow G, Fletcher RS, Barnard J, Arion D, Motakis D, Dmitrienko GI, Parniak MA. Borkow G, et al. Biochemistry. 1997 Mar 18;36(11):3179-85. doi: 10.1021/bi9624696. Biochemistry. 1997. PMID: 9115994

2

The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.

Borkow G, Arion D, Wainberg MA, Parniak MA. Borkow G, et al. Antimicrob Agents Chemother. 1999 Feb;43(2):259-63. doi: 10.1128/AAC.43.2.259. Antimicrob Agents Chemother. 1999. PMID: 9925515 Free PMC article.

3

Inhibitory potency of R-region specific antisense oligonucleotides against in vitro DNA polymerization and template-switching reactions catalysed by HIV-1 reverse transcriptase.

Borkow G, Arion D, Noronha A, Scartozzi M, Damha MJ, Parniak MA. Borkow G, et al. Int J Biochem Cell Biol. 1997 Nov;29(11):1285-95. doi: 10.1016/s1357-2725(97)00067-8. Int J Biochem Cell Biol. 1997. PMID: 9451826

4

The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase.

Barnard J, Borkow G, Parniak MA. Barnard J, et al. Among authors: borkow g. Biochemistry. 1997 Jun 24;36(25):7786-92. doi: 10.1021/bi970140u. Biochemistry. 1997. PMID: 9201921

5

Single-step purification of recombinant wild-type and mutant HIV-1 reverse transcriptase.

Fletcher RS, Holleschak G, Nagy E, Arion D, Borkow G, Gu Z, Wainberg MA, Parniak MA. Fletcher RS, et al. Among authors: borkow g. Protein Expr Purif. 1996 Feb;7(1):27-32. doi: 10.1006/prep.1996.0004. Protein Expr Purif. 1996. PMID: 9172779

6

Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase.

Borkow G, Barnard J, Nguyen TM, Belmonte A, Wainberg MA, Parniak MA. Borkow G, et al. J Virol. 1997 Apr;71(4):3023-30. doi: 10.1128/JVI.71.4.3023-3030.1997. J Virol. 1997. PMID: 9060662 Free PMC article.

7

Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase.

Wainberg MA, Hsu M, Gu Z, Borkow G, Parniak MA. Wainberg MA, et al. Among authors: borkow g. AIDS. 1996 Dec;10 Suppl 5:S3-10. doi: 10.1097/00002030-199612005-00002. AIDS. 1996. PMID: 9030390 Clinical Trial.

8

Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO).

Arion D, Fletcher RS, Borkow G, Camarasa MJ, Balzarini J, Dmitrienko GI, Parniak MA. Arion D, et al. Among authors: borkow g. Mol Pharmacol. 1996 Nov;50(5):1057-64. Mol Pharmacol. 1996. PMID: 8913335

9

The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase.

Arion D, Borkow G, Gu Z, Wainberg MA, Parniak MA. Arion D, et al. Among authors: borkow g. J Biol Chem. 1996 Aug 16;271(33):19860-4. doi: 10.1074/jbc.271.33.19860. J Biol Chem. 1996. PMID: 8702696 Free article.

10

Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide nonnucleoside compounds.

Fletcher RS, Arion D, Borkow G, Wainberg MA, Dmitrienko GI, Parniak MA. Fletcher RS, et al. Among authors: borkow g. Biochemistry. 1995 Aug 15;34(32):10106-12. doi: 10.1021/bi00032a002. Biochemistry. 1995. PMID: 7543775

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results